# The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

> **NCT03228368** · — · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 10 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab (MPDL3280A)

## Key facts

- **NCT ID:** NCT03228368
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-01
- **Primary completion:** 2018-03-01
- **Final completion:** 2018-12-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2017-07-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03228368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03228368, "The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03228368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*